OXFORD, UK - Oxford BioDynamics Plc (AIM: OBD), a biotechnology company specializing in precision clinical diagnostics, has secured a £1 million loan from Vulpes Testudo Fund to bolster its working capital and sustain its funding efforts. The interest-free loan, announced on Thursday, is unsecured and has a 90-day repayment term.
Vulpes Testudo Fund, along with Vulpes Life Sciences Fund, holds a 9.4% stake in Oxford BioDynamics, amounting to 29,653,978 ordinary shares. Both funds are managed by Vulpes Investment Management, which is under the control of Stephen Diggle, a Non-Executive Director at Oxford BioDynamics. Consequently, the loan agreement is categorized as a related party transaction according to AIM Rule 13.
The company’s board, with the exception of Stephen Diggle, has declared the loan terms fair and reasonable for shareholders after consultation with Shore Capital, the company’s Nominated Adviser. The additional funds are intended to extend the company’s cash runway, although Oxford BioDynamics anticipates the need for further financing in early Q1 2025.
Matthew Wakefield, the Non-Executive Chairman of Oxford BioDynamics, expressed gratitude towards Vulpes for the support and emphasized that the loan will give the company, along with incoming Executive Chairman Iain Ross, more time to secure additional equity funding.
Oxford BioDynamics is known for its EpiSwitch® platform, which develops blood tests for diseases such as cancer and has recently launched tests like the EpiSwitch® PSE for prostate cancer screening and EpiSwitch® CiRT for predicting responses to immuno-oncology treatments. The company operates out of Oxford, UK, with additional facilities in Maryland, USA, and Penang, Malaysia.
This financial development is based on a press release statement from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.